Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 1
2015 2
2016 2
2017 3
2018 6
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein's C-Terminal Helix.
Topacio BR, Zatulovskiy E, Cristea S, Xie S, Tambo CS, Rubin SM, Sage J, Kõivomägi M, Skotheim JM. Topacio BR, et al. Mol Cell. 2019 May 16;74(4):758-770.e4. doi: 10.1016/j.molcel.2019.03.020. Epub 2019 Apr 11. Mol Cell. 2019. PMID: 30982746 Free PMC article.
The cyclin-dependent kinases Cdk4 and Cdk6 form complexes with D-type cyclins to drive cell proliferation. A well-known target of cyclin D-Cdk4,6 is the retinoblastoma protein Rb, which inhibits cell-cycle progression until its inactivation by phosphor …
The cyclin-dependent kinases Cdk4 and Cdk6 form complexes with D-type cyclins to drive cell proliferation. A well-known target …
C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines.
Bevara GB, Naveen Kumar AD, Koteshwaramma KL, Badana A, Kumari S, Malla RR. Bevara GB, et al. Indian J Med Res. 2018 Feb;147(2):158-168. doi: 10.4103/ijmr.IJMR_51_16. Indian J Med Res. 2018. PMID: 29806604 Free PMC article.
We earlier demonstrated the isolation of 5,7-dihydroxy-2-[4'-hydroxy-3'-(methoxymethyl)phenyl]-6-C-β-glucopyranosyl flavone, a novel C-glycosyl flavone from Urginea indica bulb. ...Docking studies were performed to predict possible targets. Levels of cyclin- …
We earlier demonstrated the isolation of 5,7-dihydroxy-2-[4'-hydroxy-3'-(methoxymethyl)phenyl]-6-C-β-glucopyranosyl flavone, a novel …
Curcumin: Synthesis optimization and in silico interaction with cyclin dependent kinase.
Ahmed M, Abdul Qadir M, Imtiaz Shafiq M, Muddassar M, Hameed A, Nadeem Arshad M, Asiri AM. Ahmed M, et al. Acta Pharm. 2017 Sep 1;67(3):385-395. doi: 10.1515/acph-2017-0023. Acta Pharm. 2017. PMID: 28858834
To computationally assess its therapeutic potential against cyclin dependent kinases (CDKs), curcumin was docked in different isoforms of CDKs. ...
To computationally assess its therapeutic potential against cyclin dependent kinases (CDKs), curcumin was docked in dif …
Molecular Dynamics Mechanisms of the Inhibitory Effects of Abemaciclib, Hymenialdisine, and Indirubin on CDK-6.
Basati G, Saffari-Chaleshtori J, Abbaszadeh S, Asadi-Samani M, Ashrafi-Dehkordi K. Basati G, et al. Curr Drug Res Rev. 2019;11(2):135-141. doi: 10.2174/2589977511666191018180001. Curr Drug Res Rev. 2019. PMID: 31875784
BACKGROUND: Cyclin-Dependent Kinases-6 (CDK-6) is a serine/threonine protein kinase with regular activity in the cell cycle. ...CDK-6 docked to hymenialdisine and indirubin increased the Total Energy (TE) and decreased the radius o …
BACKGROUND: Cyclin-Dependent Kinases-6 (CDK-6) is a serine/threonine protein kinase with regular activity …
Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P, Zhang YK, Zhang XY, Wang YJ, Lu KW, Hall T, Peng R, Yang DH, Xie N, Chen ZS. Gupta P, et al. Cell Physiol Biochem. 2018;45(4):1515-1528. doi: 10.1159/000487578. Epub 2018 Feb 19. Cell Physiol Biochem. 2018. PMID: 29486476 Free article.
In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells. ...Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concentration-dependent manner. Lastly, voruciclib ex …
In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing c …
Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex.
Khuntawee W, Rungrotmongkol T, Hannongbua S. Khuntawee W, et al. J Chem Inf Model. 2012 Jan 23;52(1):76-83. doi: 10.1021/ci200304v. Epub 2011 Dec 29. J Chem Inf Model. 2012. PMID: 22172011
The cyclin dependent kinases (CDKs), each with their respective regulatory partner cyclin that are involved in the regulation of the cell cycle, apoptosis, and transcription, are potentially interesting targets for cancer therapy. The CDK6 complex with cyc
The cyclin dependent kinases (CDKs), each with their respective regulatory partner cyclin that are involved in the regu …
Artificial Intelligence Approach to Find Lead Compounds for Treating Tumors.
Chen JQ, Chen HY, Dai WJ, Lv QJ, Chen CY. Chen JQ, et al. J Phys Chem Lett. 2019 Aug 1;10(15):4382-4400. doi: 10.1021/acs.jpclett.9b01426. Epub 2019 Jul 22. J Phys Chem Lett. 2019. PMID: 31304749
All peptide database were screened by the Docking process. Modification peptides were optimized the interaction modes, and the affinities were assessed with ZDOCK protocol and Refine Docked protein protocol. ...S3, a designed peptide referred from endogenous inhibit …
All peptide database were screened by the Docking process. Modification peptides were optimized the interaction modes, and the affini …
In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD, Xu WQ, He RQ, Dang YW, Chen G, Luo DZ. Xiong DD, et al. Oncol Rep. 2019 Apr;41(4):2194-2208. doi: 10.3892/or.2019.7022. Epub 2019 Feb 19. Oncol Rep. 2019. PMID: 30816530 Free PMC article.
Eight genes [(GTPase NRas (NRAS), calcium/calmodulin‑dependent protein kinase type II subunit Gamma (CAMK2G), platelet‑derived growth factor receptor alpha (PDGFRA), calmodulin 3 (CALM3), cyclin‑dependent kinase 6 (CDK6), calcium/calmodulin‑dependent protein …
Eight genes [(GTPase NRas (NRAS), calcium/calmodulin‑dependent protein kinase type II subunit Gamma (CAMK2G), platelet‑derived growth …
Discovery of rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer.
Shi X, Li H, Shi A, Yao H, Ke K, Dong C, Zhu Y, Qin Y, Ding Y, He YH, Liu X, Li L, Lei L, Hai Q, Chen W, Leung KS, Wong MH, Kung HF, Lin MC. Shi X, et al. Oncol Rep. 2018 Sep;40(3):1592-1600. doi: 10.3892/or.2018.6533. Epub 2018 Jun 27. Oncol Rep. 2018. PMID: 29956794
We performed structure‑based virtual screening using the docking software idock, targeting an ensemble of CDK4/6 structures. ...Consistent with the expected properties of CDK4/6 inhibitors, rafoxanide significantly increased the G1 phase population. Notably, …
We performed structure‑based virtual screening using the docking software idock, targeting an ensemble of CDK4/6 structures. . …
Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6.
Yousuf M, Shamsi A, Khan P, Shahbaaz M, AlAjmi MF, Hussain A, Hassan GM, Islam A, Rizwanul Haque QM, Hassan MI. Yousuf M, et al. Int J Mol Sci. 2020 May 15;21(10):3526. doi: 10.3390/ijms21103526. Int J Mol Sci. 2020. PMID: 32429317 Free PMC article.
Cyclin-Dependent Kinase 6 (CDK6) plays an important role in cancer progression, and thus, it is considered as an attractive drug target in anticancer therapeutics. ...Molecular docking and fluorescence binding studies revealed appreciable bindin
Cyclin-Dependent Kinase 6 (CDK6) plays an important role in cancer progression, and thus, it is considered as an
22 results
Jump to page
Feedback